Ajinomoto Bio-Pharma Services
Platform Technologies

About Ajinomoto
Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a global CDMO (Contract Development and Manufacturing
Organization) that provides comprehensive services from process development to GMP manufacturing of
pharmaceutical ingredients and intermediates for small, medium and large molecules, as well as gene
therapy, as a one-stop service with bases in Belgium, India, the US and Japan.
We offer a wide range of services from pre-clinical to commercial manufacturing to meet your needs.
These services are based on our innovative proprietary platform technologies such as AJIPHASE® (Liquid
phase production for oligonucleotide and peptide), CORYNEX® (Microbial secretory production system for
small protein/peptide), and AJICAP® (site-specific conjugation and linker technology for ADC and new drug-conjugate).
Latest news
-
May 7, 2025
-
April 24, 2025
-
April 4, 2025
Our Platform Technologies and CDMO Capabilities
![]() |
Our Platform Technologies
Ajinomoto and Ajinomoto Bio-Pharma Services offers a broad range of innovative platform technologies from pre-clinical and pilot programs to commercial quantities.
Our CDMO Capabilities
Ajinomoto Bio-Pharma Services provides comprehensive services from process development to GMP manufacturing of pharmaceutical ingredients and intermediates for small, medium and large molecules, as well as gene therapy, as a one-stop service with bases in Belgium, India, the US and Japan.


For more information, please visit
Contact Us
For further information, please contact us using the link below and an Ajinomoto Bio-Pharma Services representative will contact you.